Austrália - inglês - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - pancreatic extract, quantity: 300 mg - capsule, enteric - excipient ingredients: gelatin; cetyl alcohol; dimeticone 1000; iron oxide yellow; sodium lauryl sulfate; hypromellose phthalate; macrogol 4000; iron oxide red; triethyl citrate - creon is indicated as pancreatic enzyme replacement in paediatric and adult patients with pancreatic exocrine insufficiency (pei). pancreatic exocrine insufficiency is often associated with, but not limited to: cystic fibrosis, chronic pancreatitis, pancreatic surgery, gastrointestinal bypass surgery (eg. bilroth ii gastroenterostomy), ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm)

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - pancreatic extract, quantity: 400 mg (equivalent: protease, qty 1600 ph eur unit; equivalent: lipase, qty 40000 ph eur unit; equivalent: amylase, qty 25000 ph eur unit) - capsule, enteric - excipient ingredients: hypromellose phthalate; iron oxide red; titanium dioxide; sodium lauryl sulfate; macrogol 4000; triethyl citrate; iron oxide black; iron oxide yellow; dimeticone 1000; gelatin; cetyl alcohol - creon is indicated as pancreatic enzyme replacement in paediatric and adult patients with pancreatic exocrine insufficiency (pei). pancreatic exocrine insufficiency is often associated with, but not limited to: cystic fibrosis, chronic pancreatitis, pancreatic surgery, gastrointestinal bypass surgery (eg. bilroth ii gastroenterostomy), ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm)

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

abbey laboratories pty ltd - clorsulon; ivermectin - parenteral liquid/solution/suspension - clorsulon ungrouped active 100.0 mg/ml; ivermectin anthelmintic active 10.0 mg/ml - parasiticides

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

axichem pty ltd - pyriproxyfen; liquid hydrocarbon - emulsifiable concentrate - pyriproxyfen pyridine active 100.0 g/l; liquid hydrocarbon solvent other 450.0 g/l - insecticide

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

pct holdings pty ltd - fluroxypyr as the methyl heptyl ester; n-methylpyrrolidone; liquid hydrocarbon - emulsifiable concentrate - fluroxypyr as the methyl heptyl ester pyridine-pyridinoxy active 400.0 g/l; n-methylpyrrolidone solvent other 100.0 g/l; liquid hydrocarbon solvent other 300.0 g/l - herbicide

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - itraconazole, quantity: 100 mg - capsule, hard - excipient ingredients: macrogol 20000; titanium dioxide; gelatin; hypromellose; indigo carmine; erythrosine; maize starch; sucrose - sporanox is indicated for use in adults for the treatment of: superficial dermatomycoses not responding to topical treatment. fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening. pityriasis versicolor not responding to any other treatment. vulvovaginal candidiasis not responding to topical treatment. oral candidiasis in immunocompromised patients. onychomycosis caused by dermatophytes. systemic mycoses: -systemic aspergillosis, histoplasmosis, sporotrichosis. -treatment and maintenance therapy in aids patients with disseminated or chronic pulmonary histoplasmosis infection. -treatment of oropharyngeal and/or oesophageal candidiasis when fist line systemic antifungal therapy is inappropriate or has proven ineffective. -treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. this may be due to underlying pathology,

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

boston scientific pty ltd - 38303 - radionuclide source, therapeutic, brachytherapy, manual, permanent implant - therasphere is a low toxicity, targeted liver cancer therapy made of insoluble glass beads containing radioactive yttrium-90 (y-90). the mean sphere diameter ranges from 20-30 micrometers with 22,000-73,000 microspheres per mg dose dispersed in pyrogen-free water. y-90 is a pure beta emitter and mean tissue penetration is 2.5-11mm. most of the radiation is delivered to the tumour in the first two weeks after treatment. custom dose sizes are available in 0.5gbq increments between 3-20gbq. therasphere is used in the treatment of hepatic malignancies.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - pancreatic extract, quantity: 420 mg (equivalent: lipase, qty 35000 ph eur unit; equivalent: amylase, qty 25200 ph eur unit; equivalent: protease, qty 1400 ph eur unit) - capsule - excipient ingredients: macrogol 4000; hypromellose phthalate; cetyl alcohol; triethyl citrate; dimeticone 1000; gelatin; iron oxide red; iron oxide yellow; iron oxide black; titanium dioxide; sodium lauryl sulfate - creon is indicated as pancreatic enzyme replacement in paediatric and adult patients with pancreatic exocrine insufficiency (pei). pancreatic exocrine insufficiency is often associated with, but not limited to: ? cystic fibrosis ? chronic pancreatitis ? pancreatic surgery ? gastrointestinal bypass surgery (e.g. bilroth ii gastroenterostomy) ? ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm)

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

device technologies australia pty ltd - 46902 - orbital sphere implant - an implant intended to replace the volume in the orbital cavity, that was previously occupied by the eye. it maintains the natural structure of the orbit, and provides support for the artificial eye.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

medacta australia pty ltd - 62782 - optical surgical navigation device tracking system - the nextar? tka platform is intended to be used to support the surgeon during total knee replacement procedures by providing information on bone resections, ligaments behavior, instrument and implant positioning. the nextar? tka platform is intended to be used in combination with nextar? stereotaxic instruments, the myknee? nextar? cutting guides, and general surgical instruments to implant the gmk sphere total knee system and perform ligament balancing. as an optional display, the smart glasses can be used auxiliary to the nextar platform to view the same 2d stereotaxic information as presented by the nextar platform. the smart glasses should not be relied upon solely and should always be used in conjunction with the primary computer display. the myknee? nextar cutting guides include a camera/target holder and a psi myknee? cutting guide both for tibia and femur. the myknee? cutting guides must be used as anatomical cutting blocks specific for a single patient anatomy, to assist in the positioning of total knee replacement components intraoperatively and in guiding the marking of bone before cutting. myknee? nextar tka cutting guides are for single use only. the nextar? stereotaxic instruments are intended to be used to support the surgeon during specific orthopedic surgical procedures by providing information on bone resections, ligaments behavior, instrument and implant positioning. the nextar? stereotaxic instruments, when registered with the myknee nextar tka cutting guides, provide reference to a patient?s rigid anatomical structures, such as the femur and tibia, that can be identified relative to pre-operative ct based planning.